A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Rainier Clinical Research Center, Renton, Washington
Conditions: Obesity, Cardiovascular Diseases
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Active Not Recruiting
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additiona... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Northwest Clinical Research Center, Bellevue, Washington +1 locations
Conditions: Obesity, Overweight, Obstructive Sleep Apnea, Osteoarthritis, Knee
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Active Not Recruiting
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Active Not Recruiting
The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Northwest Clinical Research Center, Bellevue, Washington
Conditions: Obesity, Overweight, Osteo Arthritis Knee
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
04/17/2025
Locations: Eastside Research Associates, Redmond, Washington +1 locations
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Recruiting
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Northwest Clinical Research Center, Bellevue, Washington +1 locations
Conditions: Obesity
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Active Not Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Central Washington Health Services Association d/b/a Confluence Health, Wenatchee, Washington
Conditions: Diabetes Mellitus, Type 2
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Active Not Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: MultiCare Rockwood Cheney Clinic, Cheney, Washington +1 locations
Conditions: Diabetes Type 2